Skip to main content

Drug Interactions between rosuvastatin and Voydeya

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rosuvastatin danicopan

Applies to: rosuvastatin and Voydeya (danicopan)

ADJUST DOSE: Coadministration with danicopan may increase the plasma concentrations and effects of rosuvastatin. The proposed mechanism is decreased clearance of rosuvastatin due to danicopan-mediated inhibition of the efflux transporter breast cancer resistance protein (BCRP). In a clinical drug interaction study, when subjects were coadministered rosuvastatin (single 20 mg dose) with danicopan at steady state (200 mg three times daily for 4 days), the peak plasma concentration (Cmax) and systemic exposure (AUC) of rosuvastatin increased by 3.3-fold and 2.2-fold, respectively. An increase in rosuvastatin-related adverse effects may occur (e.g., myopathy and rhabdomyolysis).

MANAGEMENT: If concomitant use with danicopan is required, the manufacturer advises a dose reduction of rosuvastatin to a maximum recommended daily dosage of 10 mg. Closer monitoring for adverse effects such as myopathy and rhabdomyolysis may also be advised. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.

References

  1. (2024) "Product Information. Voydeya (danicopan)." Alexion Pharmaceuticals Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer